Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404088 · ClinicalTrials.gov registry record · Phase 2
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
A Phase 2 study of Grade 3a Follicular Lymphoma and Ann Arbor Stage III Grade 2 Follicular Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT04404088: Active Phase 2 study of Grade 3a Follicular Lymphoma and Ann Arbor Stage III Grade 2 Follicular Lymphoma, sponsored by M.D. Anderson Cancer Center.
NCT04404088 is a Phase 2 study of Grade 3a Follicular Lymphoma and Ann Arbor Stage III Grade 2 Follicular Lymphoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, above the 37-participant average among 10 other Grade 3a Follicular Lymphoma trials with a reported enrollment target (62% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04404088, a Phase 2 study of Grade 3a Follicular Lymphoma and Ann Arbor Stage III Grade 2 Follicular Lymphoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib, lenalidomide, and rituximab may help to control the disease.
Primary Outcome
Will be based on Cheson, Lugano classification 2014. The number and percentage of subjects with a complete remission at the end of treatment will be tabulated.
Conditions Studied
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Rituximab
- DRUG Acalabrutinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 2 |
What the registry record for NCT04404088 still lists
NCT04404088 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, above the 37-participant average among 10 other Grade 3a Follicular Lymphoma trials with a reported enrollment target (62% higher).
The record links to 7 conditions, with Grade 3a Follicular Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Lenalidomide is the first listed.
NCT04404088 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04404088 about?
NCT04404088 is a clinical study titled "Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma". This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemother...
What is the current status of trial NCT04404088?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-07-16. Estimated completion is 2028-03-01.
What conditions does trial NCT04404088 study?
This clinical trial studies the following conditions: Grade 3a Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma.
What interventions are being tested in trial NCT04404088?
The interventions under investigation include: Lenalidomide (DRUG), Rituximab (BIOLOGICAL), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT04404088?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04404088 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Grade 3a Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04404088's enrollment target sits among peer trials
60 2nd of 10 the highest of 10 other Grade 3a Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Grade 3a Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
RECRUITING · Phase 2
-
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
RECRUITING · Phase 2
-
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
RECRUITING · Phase 2
-
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI